



Renal Cell Carcinoma

CENTER OF EXCELLENCE

Renal Cell Carcinoma



Categories of Response to First Line Vascular Endothelial Growth Factor Receptor Targeted Therapy and Overall Survival in Patients With Metastatic Renal Cell Carcinoma

RESEARCH · November 13, 2013

TAKE-HOME MESSAGE

- A retrospective study of 331 patients found minimal difference in overall survival between patients who have partial response vs stable disease on targeted therapies.
- Freedom from progression at 6 months was a stronger indicator of prolonged survival than response to treatment in patients with metastatic RCC.

- Richard Bambury, MD

ABSTRACT

INTRODUCTION

Sequential use of targeted therapy (TT) has improved overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC). The value of objective response (OR) as compared to stable disease (SD) is unclear. We aimed to investigate OR of first-line TT and its impact on OS.

MATERIAL AND METHODS

Retrospective analysis of OS among 331 mRCC patients with a first-line assessment according to RECIST 1.0. Characteristics between objective responders (complete response [CR] or partial remission [PR]), patients with SD and non-responders (progressive disease [PD] and toxicity [Tox]) were compared with the Chi-square test and the Kruskal-Wallis test. Kaplan-Meier analysis of OS and progression-free survival (PFS). Cox model analysis of Predictors of OS.

RESULTS

Best response was CR, PR, SD, PD and Tox in 9 (2.7%), 61 (18.4%), 167 (50.5%), 80 (24.2%) and 14 (4.2%) patients respectively resulting in an OR rate of 21%. Median OS in months: CR 63.2; PR 37.6; SD 35.9; PD 14.6; TOX 22.5 ($p < 0.0001$). Median PFS for responders was 14.8, 11.5 for patients with SD and 2.5 for non-responders ($p < 0.0001$). Similarly median OS was 38.7, 35.9 and 15.5 ($p < 0.00001$). Primary resistance and a first-line PFS <6 months were the strongest independent predictors of OS. The achievement of OR as compared to SD did not impact OS.

CONCLUSIONS

In our cohort of unselected patients OR was not associated with superior OS as compared to SD.

European Journal of Cancer

Categories of Response to First Line Vascular Endothelial Growth Factor Receptor Targeted Therapy and Overall Survival in Patients With Metastatic Renal Cell Carcinoma

Eur. J. Cancer 2013 Nov 13;[EPub Ahead of Print], J Busch, C Seidel, I Goranova, B Erber, R Peters, F Friedersdorff, A Magheli, K Miller, V Grünwald, S Weikert

Copyright © 2014 Elsevier Inc. All rights reserved.

Further Reading

Cytoreductive Nephrectomy in Patients With Synchronous Metastases From Renal Cell Carcinoma

Eur Urol · October 06, 2014

Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients With Renal Cell Carcinoma

Eur Urol · October 02, 2014

ESMO Interview: Maximizing Efficacy of Sunitinib in Untreated mRCC [Georg Bjarnason MD \(/Profile/938\)](/Profile/938)

Interview · October 02, 2014

Renal Carcinoma Rates Increase Among Children

Pediatrics · September 30, 2014

Association Among Socioeconomic Status, Renal Cancer Presentation, and Survival in the US**Expert Comment** [James E. Montie MD \(/Profile/891\)](/Profile/891)

Urology · September 24, 2014

The Somatic Genomic Landscape of Chromophobe RCC**Expert Comment** [Daruka Mahadevan MD, PhD \(/Profile/895\)](/Profile/895) [Bradley G Somer MD \(/Profile/420\)](/Profile/420)

Cancer · September 22, 2014

My Approach to mTOR-Induced Stomatitis [Sylvia Richey MD \(/Profile/751\)](/Profile/751) [Heather R Greene MSN, FNP, AOCNP \(/Profile/750\)](/Profile/750)


My Approach · September 22, 2014

Earlier Follow-Up Imaging After RCC Resection Might Improve Detection of Recurrence

World J Urol · September 17, 2014

Chromosome 9p Deletion in Clear Cell RCC Predicts Outcomes After Surgery

Br. J. Cancer · September 11, 2014

Growth Kinetics of cT1b and cT2 Renal Masses**Expert Comment** [Steven C. Campbell MD, PhD \(/Profile/702\)](/Profile/702)

J Urol · September 10, 2014